Neuren Pharmaceuticals Limited (NURPF)
USD 8.0
(14.29%)
USD 8.0
(14.29%)
| Year | Net Debt | Net Debt Growth |
|---|---|---|
| 2023 | -17.09 Million AUD | 57.46% |
| 2022 | -40.18 Million AUD | -9.24% |
| 2021 | -36.78 Million AUD | -52.07% |
| 2020 | -24.18 Million AUD | -74.72% |
| 2019 | -13.84 Million AUD | 41.28% |
| 2018 | -23.57 Million AUD | -400.98% |
| 2017 | -4.7 Million AUD | 6.83% |
| 2016 | -5.05 Million AUD | 69.65% |
| 2015 | -16.64 Million AUD | 20.08% |
| 2014 | -20.82 Million AUD | 14.43% |
| 2013 | -24.33 Million AUD | -373.72% |
| 2012 | -5.13 Million AUD | 31.4% |
| 2011 | -7.48 Million AUD | -626.32% |
| 2010 | -1.03 Million AUD | 69.82% |
| 2009 | -3.41 Million AUD | -164.04% |
| 2008 | -1.29 Million AUD | -153.84% |
| 2007 | 2.4 Million AUD | 125.45% |
| 2006 | -9.44 Million AUD | 19.1% |
| 2005 | -11.67 Million AUD | -3587.6% |
| 2004 | -316.59 Thousand AUD | 0.0% |
| 2003 | - AUD | 0.0% |
| 2002 | - AUD | 0.0% |
| Year | Net Debt | Net Debt Growth |
|---|---|---|
| 2024 Q2 | -2.57 Million AUD | 0.0% |
| 2024 Q1 | -2.57 Million AUD | 84.96% |
| 2023 Q1 | -38.38 Million AUD | 4.46% |
| 2023 Q4 | -17.09 Million AUD | 0.0% |
| 2023 Q2 | -38.38 Million AUD | 0.0% |
| 2023 FY | -17.09 Million AUD | 57.46% |
| 2023 Q3 | -17.09 Million AUD | 55.47% |
| 2022 Q4 | -40.18 Million AUD | 0.0% |
| 2022 Q3 | -40.18 Million AUD | -29.25% |
| 2022 FY | -40.18 Million AUD | -9.24% |
| 2022 Q1 | -31.08 Million AUD | 15.48% |
| 2022 Q2 | -31.08 Million AUD | 0.0% |
| 2021 FY | -36.78 Million AUD | -52.07% |
| 2021 Q1 | -18.22 Million AUD | 24.67% |
| 2021 Q2 | -18.22 Million AUD | 0.0% |
| 2021 Q4 | -36.78 Million AUD | 0.0% |
| 2021 Q3 | -36.78 Million AUD | -101.88% |
| 2020 Q4 | -24.18 Million AUD | 0.0% |
| 2020 Q1 | -9.17 Million AUD | 33.75% |
| 2020 Q2 | -9.17 Million AUD | 0.0% |
| 2020 Q3 | -24.18 Million AUD | -163.72% |
| 2020 FY | -24.18 Million AUD | -74.72% |
| 2019 Q1 | -17.26 Million AUD | 26.76% |
| 2019 Q4 | -13.84 Million AUD | 0.0% |
| 2019 Q3 | -13.84 Million AUD | 19.82% |
| 2019 FY | -13.84 Million AUD | 41.28% |
| 2019 Q2 | -17.26 Million AUD | 0.0% |
| 2018 Q3 | -23.57 Million AUD | -106.7% |
| 2018 Q2 | -11.4 Million AUD | 0.0% |
| 2018 Q1 | -11.4 Million AUD | -142.37% |
| 2018 FY | -23.57 Million AUD | -400.98% |
| 2018 Q4 | -23.57 Million AUD | 0.0% |
| 2017 FY | -4.7 Million AUD | 6.83% |
| 2017 Q3 | -4.7 Million AUD | -269.68% |
| 2017 Q2 | -1.27 Million AUD | 0.0% |
| 2017 Q1 | -1.27 Million AUD | 74.8% |
| 2017 Q4 | -4.7 Million AUD | 0.0% |
| 2016 Q1 | -8.13 Million AUD | 51.14% |
| 2016 FY | -5.05 Million AUD | 69.65% |
| 2016 Q4 | -5.05 Million AUD | 0.0% |
| 2016 Q3 | -5.05 Million AUD | 37.89% |
| 2016 Q2 | -8.13 Million AUD | 0.0% |
| 2015 FY | -16.64 Million AUD | 20.08% |
| 2015 Q4 | -16.64 Million AUD | 0.0% |
| 2015 Q3 | -16.64 Million AUD | 5.72% |
| 2015 Q2 | -17.65 Million AUD | 0.0% |
| 2015 Q1 | -17.65 Million AUD | 15.23% |
| 2014 Q2 | -22.46 Million AUD | 0.0% |
| 2014 FY | -20.82 Million AUD | 14.43% |
| 2014 Q4 | -20.82 Million AUD | 0.0% |
| 2014 Q3 | -20.82 Million AUD | 7.3% |
| 2014 Q1 | -22.46 Million AUD | 7.69% |
| 2013 FY | -24.33 Million AUD | -373.72% |
| 2013 Q1 | -3.27 Million AUD | 36.2% |
| 2013 Q2 | -3.44 Million AUD | -5.17% |
| 2013 Q4 | -24.33 Million AUD | 0.18% |
| 2013 Q3 | -24.37 Million AUD | -607.21% |
| 2012 Q4 | -5.13 Million AUD | 0.0% |
| 2012 FY | -5.13 Million AUD | 31.4% |
| 2011 Q4 | -7.48 Million AUD | 0.0% |
| 2011 FY | -7.48 Million AUD | -626.32% |
| 2010 FY | -1.03 Million AUD | 69.82% |
| 2010 Q4 | -1.03 Million AUD | 0.0% |
| 2009 Q4 | -3.02 Million AUD | 0.0% |
| 2009 FY | -3.41 Million AUD | -164.04% |
| 2008 Q4 | -1.29 Million AUD | 0.0% |
| 2008 FY | -1.29 Million AUD | -153.84% |
| 2007 Q4 | 2.4 Million AUD | 0.0% |
| 2007 FY | 2.4 Million AUD | 125.45% |
| 2006 FY | -9.44 Million AUD | 19.1% |
| 2006 Q4 | -9.37 Million AUD | 0.0% |
| 2005 FY | -11.67 Million AUD | -3587.6% |
| 2005 Q4 | -23.3 Million AUD | 0.0% |
| 2004 FY | -316.59 Thousand AUD | 0.0% |
| 2003 FY | - AUD | 0.0% |
| 2002 FY | - AUD | 0.0% |
| Name | Net Debt | Net Debt Difference |
|---|---|---|
| Bioxytran, Inc. | 1.89 Million USD | 1000.199% |
| Eiger BioPharmaceuticals, Inc. | 15.76 Million USD | 208.444% |
| Institute of Biomedical Research Corp. | 401.84 Thousand USD | 4353.837% |
| SQZ Biotechnologies Company | -36.23 Million USD | 52.829% |
| Intellipharmaceutics International Inc. | 2.24 Million USD | 862.365% |
| Evofem Biosciences, Inc. | 42.79 Million USD | 139.946% |
| Santhera Pharmaceuticals Holding AG | -6.3 Million USD | -171.139% |
| Propanc Biopharma, Inc. | 927.18 Thousand USD | 1943.643% |
| Marizyme, Inc. | 18.56 Million USD | 192.057% |
| Genus plc | 190.6 Million USD | 108.969% |
| Pharming Group N.V. | 109.8 Million USD | 115.568% |
| Therapeutic Solutions International, Inc. | 860.24 Thousand USD | 2087.118% |
| CNBX Pharmaceuticals Inc. | 1.21 Million USD | 1508.202% |
| Nymox Pharmaceutical Corporation | 680 Thousand USD | 2613.824% |
| ContraFect Corporation | -6.02 Million USD | -183.671% |
| RegeneRx Biopharmaceuticals, Inc. | 1.15 Million USD | 1579.45% |
| IMV Inc. | 7.67 Million USD | 322.853% |
| AXIM Biotechnologies, Inc. | 5.5 Million USD | 410.693% |
| ONE Bio Corp. | 9.04 Million USD | 289.092% |
| RVL Pharmaceuticals plc | 12.94 Million USD | 232.041% |
| Mesoblast Limited | 55.85 Million USD | 130.602% |
| MultiCell Technologies, Inc. | 90.04 USD | 18984995.602% |
| Arno Therapeutics, Inc. | - USD | Infinity% |
| Emmaus Life Sciences, Inc. | 30.55 Million USD | 155.947% |
| Genscript Biotech Corporation | -1.06 Billion USD | 98.389% |
| Neon Bloom, Inc. | 622.36 Thousand USD | 2846.624% |
| Mosaic ImmunoEngineering Inc. | 1 Million USD | 1796.311% |
| Nanobac Pharmaceuticals, Incorporated | 4.11 Million USD | 515.102% |
| Biomind Labs Inc. | 711.4 Thousand USD | 2502.861% |
| Provectus Biopharmaceuticals, Inc. | 1.99 Million USD | 954.96% |
| Oncotelic Therapeutics, Inc. | 12.8 Million USD | 233.478% |
| Skye Bioscience, Inc. | -5.72 Million USD | -198.774% |
| GlobeStar Therapeutics Corporation | 359.71 Thousand USD | 4852.161% |
| VioQuest Pharmaceuticals, Inc. | 2.23 Million USD | 864.548% |
| THC Farmaceuticals, Inc. | 139.8 Thousand USD | 12327.118% |
| PsyBio Therapeutics Corp. | 134.63 Thousand USD | 12796.173% |
| Arch Therapeutics, Inc. | 5.64 Million USD | 402.636% |
| Sienna Biopharmaceuticals, Inc. | - USD | Infinity% |
| Acro Biomedical Co., Ltd. | 19.86 Thousand USD | 86142.181% |
| Accustem Sciences Inc. | -733.97 Thousand USD | -2228.953% |
| EV Biologics, Inc. | 1.36 Million USD | 1349.588% |
| Q BioMed Inc. | 4.06 Million USD | 521.034% |
| GB Sciences, Inc. | 1.74 Million USD | 1078.3% |
| Alpha Cognition Inc. | -183.78 Thousand USD | -9200.934% |
| CSL Limited | 10.52 Billion USD | 100.162% |
| Agentix Corp. | 37.63 Thousand USD | 45525.314% |
| American Oriental Bioengineering, Inc. | 60.54 Million USD | 128.233% |
| Enzolytics Inc. | 981.65 Thousand USD | 1841.343% |
| TetraLogic Pharmaceuticals Corporation | - USD | Infinity% |
| Resverlogix Corp. | 6.45 Million USD | 364.982% |
| Nuo Therapeutics, Inc. | -673.08 Thousand USD | -2439.634% |
| MetaStat, Inc. | - USD | Infinity% |
| Curative Biotechnology, Inc. | 2.2 Million USD | 876.301% |
| argenx SE | -2.02 Billion USD | 99.157% |
| Northwest Biotherapeutics, Inc. | 43.43 Million USD | 139.356% |
| HST Global, Inc. | 96.79 Thousand USD | 17760.368% |
| Enzon Pharmaceuticals, Inc. | -47.01 Million USD | 63.639% |
| Wesana Health Holdings Inc. | 206.21 Thousand USD | 8389.326% |
| Halberd Corporation | 144.72 Thousand USD | 11911.693% |
| Endonovo Therapeutics, Inc. | 7.07 Million USD | 341.749% |
| Inhibitor Therapeutics, Inc. | -8.83 Million USD | -93.373% |
| Zenith Capital Corp. | 10.06 Thousand USD | 169952.941% |
| RespireRx Pharmaceuticals Inc. | 2.7 Million USD | 731.097% |
| GeneThera, Inc. | - USD | Infinity% |
| Sigyn Therapeutics, Inc. | 2.38 Million USD | 816.419% |
| AVAX Technologies, Inc. | -5.9 Million USD | -189.571% |
| WPD Pharmaceuticals Inc. | 164.5 Thousand USD | 10490.921% |
| Cotinga Pharmaceuticals Inc. | -18.31 Thousand USD | -93218.048% |
| Ember Therapeutics, Inc. | 200.43 Thousand USD | 8628.578% |
| Anthera Pharmaceuticals, Inc. | - USD | Infinity% |
| Adynxx, Inc. | - USD | Infinity% |
| NovAccess Global Inc. | 2.17 Million USD | 884.681% |
| Helix BioMedix, Inc. | -2.57 Million USD | -565.128% |
| Capstone Therapeutics Corp. | 20.27 Million USD | 184.307% |
| Kadimastem Ltd | -253.1 Thousand USD | -6653.799% |
| VitaSpring Biomedical Co. Ltd. | - USD | Infinity% |
| BioStem Technologies, Inc. | 4.47 Million USD | 482.244% |
| Oncology Pharma Inc. | - USD | Infinity% |
| Reve Technologies, Inc. | 201.25 Thousand USD | 8593.744% |
| Burzynski Research Institute, Inc. | -1310.00 USD | -1304785.496% |
| LadRx Corporation | -2.03 Million USD | -739.394% |
| Cell Source, Inc. | 9.23 Million USD | 285.161% |
| ProtoKinetix, Incorporated | -20.4 Thousand USD | -83661.27% |
| Regen BioPharma, Inc. | 635.16 Thousand USD | 2791.261% |
| Regen BioPharma, Inc. | 635.16 Thousand USD | 2791.261% |
| Affymax, Inc. | -5.59 Million USD | -205.414% |
| Mobile Lads Corp. | 484.23 Thousand USD | 3630.126% |
| Itoco Inc. | 228.3 Thousand USD | 7587.352% |
| Rasna Therapeutics, Inc. | 135.98 Thousand USD | 12670.134% |
| Pathfinder Cell Therapy, Inc. | 4.95 Million USD | 444.846% |
| International Stem Cell Corporation | 2.59 Million USD | 760.0% |
| CytoDyn Inc. | 20.26 Million USD | 184.365% |
| Claritas Pharmaceuticals, Inc. | - USD | Infinity% |
| NDT Pharmaceuticals Inc. | -647.00 USD | -2641940.185% |
| NanoSphere Health Sciences Inc. | -9268.34 USD | -184334.322% |
| Qrons Inc. | 351.42 Thousand USD | 4964.168% |
| Alseres Pharmaceuticals, Inc. | 7.7 Million USD | 321.827% |
| SYBLEU INC | 473.71 Thousand USD | 3708.506% |
| Advanced Proteome Therapeutics Corporation | - USD | Infinity% |
| Nascent Biotech, Inc. | -249.62 Thousand USD | -6748.009% |
| Rebus Holdings, Inc. | 305 Thousand USD | 5704.59% |
| GlobeImmune, Inc. | - USD | Infinity% |
| ImmunoCellular Therapeutics, Ltd. | 4.45 Million USD | 483.53% |
| Predictive Technology Group, Inc. | - USD | Infinity% |
| ProText Mobility, Inc. | 62.41 Thousand USD | 27488.525% |
| Cardax, Inc. | - USD | Infinity% |
| VG Life Sciences Inc. | 2.18 Million USD | 883.805% |
| Kaleido Biosciences, Inc. | - USD | Infinity% |
| Advaxis, Inc. | 3.43 Million USD | 597.787% |
| Adhera Therapeutics, Inc. | 8.55 Million USD | 299.86% |
| RenovaCare, Inc. | - USD | Infinity% |
| Regnum Corp. | 772.6 Thousand USD | 2312.509% |
| Innovation Pharmaceuticals Inc. | -1.25 Million USD | -1267.52% |
| Neutra Corp. | 52.18 Thousand USD | 32855.284% |
| Windtree Therapeutics, Inc. | -2.48 Million USD | -586.782% |
| PureTech Health plc | -167.19 Million USD | 89.776% |
| Coeptis Therapeutics, Inc. | -244.9 Thousand USD | -6879.764% |
| IXICO plc | -4.44 Million USD | -284.603% |
| IntelGenx Technologies Corp. | 13.21 Million USD | 229.314% |
| Gelesis Holdings, Inc. | 54.85 Million USD | 131.164% |
| CSL Limited | 10.52 Billion USD | 100.162% |
| Cellectis S.A. | -43.81 Million USD | 60.989% |